Molecular & Cellular Toxicology

The Korean Society of Toxicogenomics and Toxicoproteomics (대한독성유전 단백체학회)
권호 표지

Immunoadjuvanticity of Novel CpG ODN (Oligodeoxynucleotide)

  • Park, Su-Jung (Department of Microbiology, Yonsei University Wonju College of Medicine) ;
  • Cho, Hyeon-Cheol (Department of Microbiology, Yonsei University Wonju College of Medicine) ;
  • Bae, Keum-Seok (Department of General Surgery, Yonsei University Wonju College of Medicine) ;
  • Kim, Soo-Ki (Department of Microbiology, Yonsei University Wonju College of Medicine)
  • Published : 2007.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

In the course of novel TLR (Toll like receptor) 9 ligand, we found novel CpG ODN (Oligodeoxynucleotide) was active in augmenting antibody in mice. However, immune mechanism of new CpG ODNs is unclear. To clarify this, we examined immunoadjuvanticity by employing in vitro and in vivo immune profiles. In brief, in vitro treatment of novel CpG ODN upregulated the expression of TNF-$\alpha$, IL-6, and IL-12 mRNA in macrophages as well as that of IFN-$gamma$ mPNA in mouse splenocytes. In parallel, in vivo injection of novel CpG ODN directly activates macrophages and splenocytess, consequently upregulating MHC class II and CD86. Finally, we demonstrated anti-HBs antibody augmentation of novel CpG ODN. Collectively, this data indicates that novel CpG ODN is immunoadjuvant armed with Th1 typed immune machinery.

Keywords

References

  1. Chuang, T. H. et al. Toll-like receptor 9 mediates CpG-DNA signaling. Journal of Leukocyte Biology 71:538-544 (2002)
  2. Krieg, A. M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica Acta 1489:107-116 (1999) https://doi.org/10.1016/S0167-4781(99)00147-5
  3. Bhattacharjee, R. N. & Akira, S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Reviews in Medicinal Chemistry 6:287-291 (2006) https://doi.org/10.2174/138955706776073411
  4. Verthelyi, D. & Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clinical Immunology Orlando, Fla 109:64-71 (2003) https://doi.org/10.1016/S1521-6616(03)00202-X
  5. Becker, Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer research 26:1113-1134 (2006)
  6. Carpentier, A. et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology 8:60-66 (2006) https://doi.org/10.1215/S1522851705000475
  7. Carpentier, A. F., Auf, G. & Delattre, J. Y. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci. 8:e115-127 (2003) https://doi.org/10.2741/934
  8. Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Current Opinion in Microbiology 6:472-477 (2003) https://doi.org/10.1016/j.mib.2003.09.007
  9. Cooper, C. L. et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143 (2004) https://doi.org/10.1016/j.vaccine.2004.01.058
  10. Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioatemodified oligonucleotides. J. Immunol. 174:605-608 (2005) https://doi.org/10.4049/jimmunol.174.2.605
  11. Link, B. K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29: 558-568 (2006) https://doi.org/10.1097/01.cji.0000211304.60126.8f
  12. Mutwiri, G. K., Nichani, A. K., Babiuk, S. & Babiuk, L. A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control Release 97:1-17 (2004) https://doi.org/10.1016/j.jconrel.2004.02.022